Time to First Patient Access is the count of days between approval and the first patient actually receiving a therapy, market by market. On its own it is one number. Shared, it becomes a benchmark the whole field can improve against.
Today each team tends to absorb a slow launch alone, in private, and describe it as a success in public. A common, transparent benchmark replaces that with a shared baseline, so good practice can be examined, challenged and improved together.
A shared unit lets a team see its own time to access against a credible reference for its drug type, indication and markets.
Measuring the days forward, rather than explaining them afterward, keeps intervention possible before value and access leak away.
When the measure is common, every launch adds to a shared body of knowledge instead of a private post mortem.
A baseline everyone recognizes is how launch excellence stops being a one time result and becomes a repeatable standard.
The TFPA Global Index is a shared benchmark for time to first patient access, currently in development. It is being shaped with the people who run launches, so it reflects the reality of the work rather than a view handed down to them.
Inside BrandLaunchX, the same forward looking thinking runs through Plannor, Predictor, Recommendor and Accelerator, which help teams plan, see risk early, choose a recovery path, and hold the plan as conditions change.
Tell us your drug type and your two hardest markets, and we will share how we are thinking about the days for launches like yours.
Sources: EFPIA Patients W.A.I.T. Indicator 2025; BrandLaunchX founding dataset. TFPA benchmarking is in development and is not described here as a live platform feature.
